Zosano Pharma Corporation (ZSAN)

Symbol Overview


Latest Zosano Pharma Corporation (ZSAN) company news

Zosano Announces Publication on Adhesive Dermally-Applied Microarray (ADAM™) Technology for the Delivery of Zolmitriptan in Migraine in Journal of Pharmaceutics

FREMONT, Calif., June 20, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announces the recent publication of a peer-reviewed paper regarding ADAM technology for the delivery of zolmitriptan in the Journal of Pharmaceutics.

“Our in vitro study presents guidance on use of the appropriate skin model to assess intracutaneous delivery of compounds using the ADAM platform.  This particular study, assessing the intracutaneous delivery of zolmitriptan, is the first of its kind and we are excited to present the results,” said Hayley Lewis, senior vice president, operations at Zosano Pharma.

Data published in the Journal of Pharmaceutics evaluated how different in vitro skin models influenced the absorption of zolmitriptan with ADAM technology. This standardized method of testing produced a model for evaluating the efficiency of intracutaneous delivery of zolmitriptan.  The model will be helpful as Zosano continues to assess the efficiency of small molecules delivered with ADAM.

About M207

M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano's proprietary ADAM technology.  Zosano's ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan.  The drug-coated microneedles physically break through the stratum corneum and penetrate into the epidermis and dermis, where the dry drug coating is dissolved by the surrounding skin interstitial fluid.  In February 2017, the Company announced statistically significant results from the ZOTRIP pivotal study, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.  In November 2017, the Company announced the initiation of its long-term safety study evaluating M207 and expects to file an NDA for M207 in the fourth quarter of 2019.

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
John Walker
Chief Executive Officer and Chairman of the Board
510-745-1200

Media Contact:
Sara Zelkovic
LifeSci Public Relations
[email protected]
212-916-2575

Market Trends Toward New Normal in ANSYS, Pearson, Qualys, H. B. Fuller, Cabot Microelectronics, and Zosano Pharma — Emerging Consolidated Expectations, Analyst Ratings

NEW YORK, May 31, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ANSYS, Inc. (ANSS), Pearson, PLC (PSO), Qualys, Inc. (QLYS), H. B. Fuller Company (FUL), Cabot Microelectronics Corporation (CCMP), and Zosano Pharma Corporation (ZSAN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ANSS DOWNLOAD: http://Fundamental-Markets.com/register/?so=ANSS
PSO DOWNLOAD: http://Fundamental-Markets.com/register/?so=PSO
QLYS DOWNLOAD: http://Fundamental-Markets.com/register/?so=QLYS
FUL DOWNLOAD: http://Fundamental-Markets.com/register/?so=FUL
CCMP DOWNLOAD: http://Fundamental-Markets.com/register/?so=CCMP
ZSAN DOWNLOAD: http://Fundamental-Markets.com/register/?so=ZSAN

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine ANSYS, Inc. (ANSS), Pearson, PLC (PSO), Qualys, Inc. (QLYS), H. B. Fuller Company (FUL), Cabot Microelectronics Corporation (CCMP), and Zosano Pharma Corporation (ZSAN) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed May 25th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

ANSYS, INC. (ANSS) REPORT OVERVIEW

ANSYS's Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, ANSYS reported revenue of $282.87MM vs $253.41MM (up 11.63%) and basic earnings per share $1.00 vs $0.74 (up 35.14%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, ANSYS reported revenue of $1,095.25MM vs $988.47MM (up 10.80%) and basic earnings per share $3.05 vs $3.05 (unchanged). ANSYS is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.89. The estimated EPS forecast for the next fiscal year is $4.95 and is expected to report on February 20th, 2019.

To read the full ANSYS, Inc. (ANSS) report, download it here: http://Fundamental-Markets.com/register/?so=ANSS

-----------------------------------------

PEARSON, PLC (PSO) REPORT OVERVIEW

Pearson's Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, Pearson reported revenue of $5,816.35MM vs $6,169.33MM (down 5.72%) and basic earnings per share $0.64 vs -$3.89.

To read the full Pearson, PLC (PSO) report, download it here: http://Fundamental-Markets.com/register/?so=PSO

-----------------------------------------

QUALYS, INC. (QLYS) REPORT OVERVIEW

Qualys' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Qualys reported revenue of $64.88MM vs $53.12MM (up 22.13%) and basic earnings per share $0.24 vs $0.60 (down 60.00%). For the twelve months ended December 31st, 2017 vs December 31st, 2016, Qualys reported revenue of $230.83MM vs $197.93MM (up 16.62%) and basic earnings per share $1.08 vs $0.55 (up 96.36%). Qualys is expected to report earnings on August 1st, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.18. The estimated EPS forecast for the next fiscal year is $0.95 and is expected to report on February 11th, 2019.

To read the full Qualys, Inc. (QLYS) report, download it here: http://Fundamental-Markets.com/register/?so=QLYS

-----------------------------------------

H. B. FULLER COMPANY (FUL) REPORT OVERVIEW

H. B. Fuller's Recent Financial Performance

For the three months ended February 28th, 2018 vs February 28th, 2017, H. B. Fuller reported revenue of $713.08MM vs $503.32MM (up 41.67%) and basic earnings per share $0.94 vs $0.29 (up 224.14%). For the twelve months ended November 30th, 2017 vs November 30th, 2016, H. B. Fuller reported revenue of $2,306.04MM vs $2,094.61MM (up 10.09%) and basic earnings per share $1.16 vs $2.48 (down 53.23%). H. B. Fuller is expected to report earnings on June 27th, 2018. The report will be for the fiscal period ending May 31st, 2018. The reported EPS for the same quarter last year was $0.62. The estimated EPS forecast for the next fiscal year is $4.02 and is expected to report on January 22nd, 2019.

To read the full H. B. Fuller Company (FUL) report, download it here: http://Fundamental-Markets.com/register/?so=FUL

-----------------------------------------

CABOT MICROELECTRONICS CORPORATION (CCMP) REPORT OVERVIEW

Cabot Microelectronics' Recent Financial Performance

For the three months ended March 31st, 2018 vs March 31st, 2017, Cabot Microelectronics reported revenue of $142.98MM vs $119.18MM (up 19.96%) and basic earnings per share $1.16 vs $0.73 (up 58.90%). For the twelve months ended September 30th, 2017 vs September 30th, 2016, Cabot Microelectronics reported revenue of $507.18MM vs $430.45MM (up 17.83%) and basic earnings per share $3.40 vs $2.43 (up 39.92%). Cabot Microelectronics is expected to report earnings on July 26th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was $0.81.

To read the full Cabot Microelectronics Corporation (CCMP) report, download it here: http://Fundamental-Markets.com/register/?so=CCMP

-----------------------------------------

ZOSANO PHARMA CORPORATION (ZSAN) REPORT OVERVIEW

Zosano Pharma's Recent Financial Performance

Zosano Pharma is expected to report earnings on August 9th, 2018. The report will be for the fiscal period ending June 30th, 2018. The reported EPS for the same quarter last year was -$3.40.

To read the full Zosano Pharma Corporation (ZSAN) report, download it here: http://Fundamental-Markets.com/register/?so=ZSAN

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at [email protected]

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: [email protected]

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at [email protected]

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks

Stock Research Monitor: VYGR, VTVT, and ZSAN

LONDON, UK / ACCESSWIRE / May 30, 2018 / If you want a free Stock Review on VVUS sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com reexplores the Biotechnology industry, which uses biological systems or living organisms for the development of its products, mostly biopharmaceutical drugs. Under evaluation this morning are these four equities: VIVUS Inc. (NASDAQ: VVUS), Voyager Therapeutics Inc. (NASDAQ: VYGR), vTv Therapeutics Inc. (NASDAQ: VTVT), and Zosano Pharma Corp. (NASDAQ: ZSAN). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

VIVUS

Shares in Campbell, California headquartered VIVUS Inc. plummeted 14.00%, ending Tuesday's trading session at $0.79. The stock recorded a trading volume of 3.25 million shares, which was higher than its three months average volume of 1.27 million shares. The Company's shares have surged 105.87% in the last month and 77.39% over the last three months. The stock is trading 62.32% and 24.77% above its 50-day and 200-day moving averages, respectively. Moreover, shares of VIVUS, which develops and commercializes novel therapeutic products to address unmet medical needs in human health in the US and the EU, have a Relative Strength Index (RSI) of 62.84.

On May 01st, 2018, VIVUS announced that it has entered into a definitive agreement to acquire all product rights for PANCREAZE® (pancrelipase) Delayed-Release Capsules in the US and Canada held by Janssen Pharmaceuticals, Inc., subject to certain closing conditions, including Hart-Scott-Rodino review. This is the first of what the Company expects will be a series of product acquisitions designed to generate revenue and strengthen its financial position. Get the full research report on VVUS for free by clicking below at:

www.wallstequities.com/registration/?symbol=VVUS

Voyager Therapeutics

Cambridge, Massachusetts headquartered Voyager Therapeutics Inc.'s stock rose 2.53%, closing the day at $20.28 with a total trading volume of 297,175 shares. The Company's shares have advanced 8.92% in the past month and 126.34% over the past year. The stock is trading 6.82% and 12.36% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Voyager Therapeutics, which focuses on the development of treatments for patients suffering from severe neurological diseases, have an RSI of 57.65.

On May 10th, 2018, Voyager Therapeutics reported its Q1 2018 results. GAAP net loss for the quarter was $19.9 million; collaboration revenue was $0.9 million; research and development expenses were $14.9 million; and general and administrative expenses were $7.2 million. As of March 31st, 2018, cash, cash equivalents, and marketable debt securities were $218.2 million. Access the free research report on VYGR now by signing up at:

www.wallstequities.com/registration/?symbol=VYGR

vTv Therapeutics

On Tuesday, shares in High Point, North Carolina headquartered vTv Therapeutics Inc. recorded a trading volume of 179,053 shares. The stock ended the day 1.81% lower at $1.63. The Company's shares are trading below their 50-day moving average by 33.73%. Furthermore, shares of vTv Therapeutics, which discovers, develops, and sells orally administered small molecule drug candidates worldwide, have an RSI of 38.60.

On May 15th, 2018, vTv Therapeutics reported its results for Q1 ended March 31st, 2018. R&D expenses were $8.9 million in Q1 2018, G&A expenses were $2.3 million, and GAAP net loss per share was $0.30. As of March 31st, 2018, cash and cash equivalents were $6.5 million. Are you already registered with Wall St. Equities? Do so now for free, and get the report on VTVT at:

www.wallstequities.com/registration/?symbol=VTVT

Zosano Pharma

Fremont, California headquartered Zosano Pharma Corp.'s stock climbed 2.05%, finishing yesterday's session at $3.99 with a total trading volume of 176,494 shares. The stock is trading below their 50-day moving average by 36.81%. Shares of the Company, which focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology, have an RSI of 40.52.

On May 22nd, 2018, Zosano Pharma announced that Steven A. Elms, Managing Partner at Aisling Capital, has been appointed to its Board of Directors. Aisling was a lead investor in the follow-on financing that the Company recently completed in early-April. Aspiring Member, please take a moment to register below for your free research report on ZSAN at:

www.wallstequities.com/registration/?symbol=ZSAN

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

Zosano Announces Publication of Most Bothersome Symptom Data from the ZOTRIP Pivotal Study in Headache: The Journal of Head and Face Pain

FREMONT, Calif., May 23, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that Headache, the Journal of Head and Face Pain, has published the post-hoc analysis on the use of most bothersome symptom (MBS) as a co-primary endpoint from the Company’s ZOTRIP pivotal study.

Headache published the paper titled “Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post-Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial”. The paper analyzes the positive MBS results from Zosano’s ZOTRIP pivotal study, a multi-center, double-blind, placebo-controlled trial demonstrating the efficacy and safety of M207, Zosano’s novel proprietary formulation of zolmitriptan using its ADAM technology.  The ZOTRIP pivotal study, evaluating ADAM zolmitriptan for the acute treatment of migraine, was one of the first large studies to incorporate MBS freedom and pain freedom as co-primary endpoints, per recently issued guidance by the US Food and Drug Administration.  MBS freedom at two hours was observed in 68% of M207 3.8 mg subjects as compared to 43% of placebo subjects (P < .01).

“We are pleased to see this aspect of the ZOTRIP pivotal study published and hope that the results and discussion will be helpful to others designing and interpreting trials of acute treatment of migraine,” said Dr. Don Kellerman, Vice President of Clinical Development.  “Since the time of our manuscript submission, several other trials have reported results using these coprimary endpoints, and we look forward to their publication.”

About Zosano Pharma

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using our proprietary ADAM technology.  The Company previously announced positive results from our ZOTRIP pivotal study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine, and is currently conducting a long-term safety study of M207.  Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to subjects, for markets where subjects remain underserved by existing therapies. The Company anticipates that its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

About M207

M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano's proprietary ADAM technology.  Zosano's ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan.  Our ADAM technology delivers drug by abrading the stratum corneum and allowing drug to be absorbed into the microcapillary system of the skin.  In February 2017, the Company announced statistically significant results from the ZOTRIP pivotal study, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.  In November 2017, the Company announced the initiation of its long-term safety study evaluating M207 and expects to file an NDA for M207 in the fourth quarter of 2019.

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
John Walker
Chief Executive Officer and Chairman of the Board
510-745-1200


Zosano Appoints Steven A. Elms to Board of Directors

FREMONT, Calif., May 22, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”) a clinical-stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using its proprietary Adhesive Dermally-Applied Microarray (“ADAM™”) technology, today announced that Steven A. Elms, Managing Partner at Aisling Capital, has been appointed to the Company’s Board of Directors. Aisling was a lead investor in the follow-on financing that Zosano recently completed in early-April.

"On behalf of our entire Board, I am pleased to welcome Steven as a member of our Board of Directors," commented John Walker, Chief Executive Officer and Chairman of the Board. “Steven’s investment banking and Wall Street experience make him an ideal addition to our Board. He adds to the strong industry experience already represented on our Board with his working knowledge of M&A, financings and the full range of capital market transactions. We look forward to having his perspective available as we advance our strategic opportunities.”

“I am pleased to join the Zosano Board,” commented Mr. Elms. “I look forward to working to maximize the value of the Company and its technology and I am especially excited about the commercial potential of Zosano’s zolmitriptan product for migraine, M207."

Mr. Elms joined Aisling in July of 2000 and currently serves as one of the Managing Partners. Previously, he was a Principal in the Life Sciences Investment Banking Group of H&Q. During his five years at H&Q, Mr. Elms was involved in over 60 financing and M&A transactions, helping clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales representative for Marion Laboratories and two years as a consultant for The Wilkerson Group.

About Zosano Pharma

Zosano Pharma Corporation is a clinical stage biopharmaceutical company focused on providing rapid systemic administration of therapeutics to subjects using our proprietary ADAM technology.  The Company previously announced positive results from our ZOTRIP study that evaluated M207, which is our proprietary formulation of zolmitriptan delivered via our ADAM technology, as an acute treatment for migraine, and is currently conducting a long-term safety study of M207.  Zosano is focused on developing products where rapid administration of established molecules with known safety and efficacy profiles provides an increased benefit to subjects, for markets where subjects remain underserved by existing therapies. The Company anticipates that its current and future development programs may enable the Company to utilize a regulatory pathway that would streamline clinical development and accelerate the path towards commercialization. Learn more at www.zosanopharma.com.

About M207

M207 is our proprietary formulation of zolmitriptan delivered utilizing Zosano's proprietary ADAM technology.  Zosano's ADAM technology consists of titanium microprojections coated with drug, and in the case of M207, our formulation of zolmitriptan.  Our ADAM technology delivers drug by abrading the stratum corneum and allowing drug to be absorbed into the microcapillary system of the skin.  In February 2017, the Company announced statistically significant results from the ZOTRIP trial, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours.  In November 2017, the Company announced the initiation of its long-term safety study evaluating M207 and expects to file an NDA for M207 in the fourth quarter of 2019.

Forward-Looking Statements

This press release contains forward-looking statements regarding the timing of expected clinical development milestones, sufficiency of our capital resources and need for future funding and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Contact:
John Walker
Chief Executive Officer and Chairman of the Board
510-745-1200


Leave a Reply

Your email address will not be published. Required fields are marked *